Results 51 to 60 of about 63,989 (248)
Clinical and applied thrombosis/hemostasis, 2022 Direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) prevention after major gynecological cancer surgery might be an alternative to parenteral low-molecular-weight heparin (LMWH). Patients undergoing major gynecological cancer surgery were
André Luiz Malavasi Longo de Oliveira +18 more
semanticscholar +1 more source
Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation [PDF]
, 2019 © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which ...
Arachchillage, Deepa RJ +7 more
core +3 more sources
Scientific Reports, 2017 Rivaroxaban is an oral direct factor Xa inhibitor approved for the treatment of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. Despite its efficacy, rivaroxaban therapy results in adverse effects and complications,
Dan Yang +5 more
doaj +1 more source
Managing atrial fibrillation in the global community: The European perspective. [PDF]
, 2013 Atrial fibrillation is a common, global problem, with great personal, economic and social burdens. As populations age it increases in prevalence and becomes another condition that requires careful chronic management to ensure its effects are minimised ...
Camm, AJ +3 more
core +1 more source
, 2015 The bottom line Clarify the warfarin dose that the patient is taking, and check for co-existing problems (such as liver disease or cancer), dietary changes, and intake of alcohol and other drugs that may increase risk of bleeding or affect ...
Chevassut, Timothy J +2 more
core +1 more source
The Effect of Rivaroxaban on CYP4F2 and Transcription Factors’ Activity in HUVECs
Applied Sciences, 2021 Interindividual variabilities between patients taking the anticoagulant rivaroxaban are a result of hepatic metabolism by CYP 450 enzymes. The objective of this study was to evaluate the impact of rivaroxaban on CYP4F2 and transcription factors’ activity
Ieva Ciapiene +9 more
doaj +1 more source
European Heart Journal - Cardiovascular Pharmacotherapy, 2022 AIMS The advantages of direct oral anticoagulants (DOACs) over warfarin are well established in atrial fibrillation (AF) patients, however, studies that can guide in the selection between different DOACs are limited.
Y. Talmor-Barkan +6 more
semanticscholar +1 more source
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. [PDF]
, 2014 Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in ...
Amarenco, P +6 more
core +2 more sources
TH Open, 2017 Background The noninterventional XALIA study compared rivaroxaban with standard anticoagulation for deep vein thrombosis treatment. This substudy describes the demographics, clinical characteristics, and outcomes of the patients with cancer.
Walter Ageno +8 more
doaj +1 more source
Clinical and laboratory practice for lupus anticoagulant testing : an International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey [PDF]
, 2019 Background Current guidelines have contributed to more uniformity in the performance and interpretation of lupus anticoagulant (LA) testing. However, points to reconsider include testing for LA in patients on anticoagulation, cut-off values, and ...
Cohen, Hannah +3 more
core +2 more sources